Clinical trial NCT01298336 - References

Atypical; Mycobacterium, Pulmonary, Tuberculous — Treatment of Mycobacterium Xenopi Pulmonary Infection

Citation(s)

•   Alcaide F, Calatayud L, Santín M, Martín R
  Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother. 2004 Dec;48(12):4562-5.
•   Alfandari S
  Recommandations du C-CLIN Paris Nord pour le diagnostic et le traitement des infections ostéo-articulaires à Mycobacterium xenopi. Med Mal Infect 28 :231-234, 1998.
•   American Thoracic Society
  Diagnosis standards and classification of tuberculosis and other mycobacterial diseases. New York: American Lung Association, 1974:25
•   Andréjak C, Lescure FX, Douadi Y, Laurans G, Smail A, Duhaut P, Jounieaux V, Schmit JL
  Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. J Infect. 2007 Jul;55(1):34-40. Epub 2007 Mar 13.
•   Andréjak C, Lescure FX, Pukenyte E, Douadi Y, Yazdanpanah Y, Laurans G, Schmit JL, Jounieaux V; Xenopi Group
  Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax. 2009 Apr;64(4):291-6. doi: 10.1136/thx.2008.096842. Epub 2008 Dec 3.
•   Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, Sørensen HT, Lescure FX, Thomsen RW
  Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010 Mar 1;181(5):514-21. doi: 10.1164/rccm.200905-0778OC. Epub 2009 Dec 10.
•   Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP
  Pulmonary infection with mycobacterium xenopi: review of treatment and response. Thorax. 1984 May;39(5):376-82.
•   Baugnée PE, Pouthier F, Delaunois L
  [Pulmonary mycobacteriosis due to Mycobacterium xenopi" in-vitro sensitivity to classical antitubercular agents and clinical development]. Acta Clin Belg. 1996;51(1):19-27. French.
•   Bégaud B, Evreux JC, Jouglard J, Lagier G
  [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985 Mar-Apr;40(2):111-8. French.
•   Berlin OG, Young LS, Floyd-Reising SA, Bruckner DA
  Comparative in vitro activity of the new macrolide A-56268 against mycobacteria. Eur J Clin Microbiol. 1987 Aug;6(4):486-7.
•   Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, Young LS
  Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother. 2001 Jan;45(1):217-22.
•   Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS
  Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis. 2003 Jun 15;187(12):1977-80. Epub 2003 Jun 4.
•   Costrini AM, Mahler DA, Gross WM, Hawkins JE, Yesner R, D'Esopo ND
  Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis. 1981 Jan;123(1):104-9.
•   Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C, Lozniewski A, Maugein J; French Mycobacteria Study Group
  Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J. 2006 Dec;28(6):1211-5.
•   Dauendorffer JN, Laurain C, Weber M, Dailloux M
  In vitro sensitivity of Mycobacterium xenopi to five antibiotics. Pathol Biol (Paris). 2002 Dec;50(10):591-4.
•   Dautzenberg B, Papillon F, Lepitre M, Truffot-Pernod C, Chauvin JP
  Mycobacterium xenopi infections treated with clarithromycine-containing regimens. Annual meeting, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
•   Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP
  Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest. 1995 Apr;107(4):1035-40.
•   Diagnosis and treatment of disease caused by nontuberculous mycobacteria
  This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 2):S1-25. Review.
•   Falkinham JO 3rd
  Nontuberculous mycobacteria in the environment. Clin Chest Med. 2002 Sep;23(3):529-51. Review.
•   Fraschini F, Scaglione F, Pintucci G, Maccarinelli G, Dugnani S, Demartini G
  The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother. 1991 Feb;27 Suppl A:61-5.
•   Gillespie SH, Billington O
  Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother. 1999 Sep;44(3):393-5.
•   Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH
  The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003 Dec 1;168(11):1342-5. Epub 2003 Aug 13.
•   Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America
  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. Review. Erratum in: Am J Respir Crit Care Med. 2007 Apr 1;175(7):744-5. Dosage error in article text.
•   Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr
  Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis. 2000 Feb;30(2):288-92.
•   Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr
  Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis. 1996 Nov;23(5):983-9.
•   Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP
  Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008 Jul;63(7):627-34. doi: 10.1136/thx.2007.087999. Epub 2008 Feb 4. Erratum in: Thorax. 2008 Sep;63(9):844.
•   Jenkins PA, Campbell IA; Research Committee of The British Thoracic Society
  Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. Respir Med. 2003 Apr;97(4):439-44.
•   Klemens SP, Cynamon MH
  Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob Agents Chemother. 1994 Jul;38(7):1455-9.
•   Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J
  Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother. 2001 Nov;45(11):3229-30.
•   Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999
  Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 2000 Mar;55(3):210-8.
•   Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Köksalan K, Pereira MF, Rodrigues F, Pfyffer GE, Portaels F, Urgell JR, Rüsch-Gerdes S, Tortoli E, Vincent V, Watt B; Spanish Group for Non-Tuberculosis Mycobacteria
  Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis. 2004 Oct;8(10):1186-93.
•   Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F
  Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs. 2007;67(14):2077-99. Review.
•   Rhodes VA, McDaniel RW
  The Index of Nausea, Vomiting, and Retching: a new format of the lndex of Nausea and Vomiting. Oncol Nurs Forum. 1999 Jun;26(5):889-94.
•   Rodriguez Díaz JC, López M, Ruiz M, Royo G
  In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents. 2003 Jun;21(6):585-8.
•   RUNYON EH
  Anonymous mycobacteria in pulmonary disease. Med Clin North Am. 1959 Jan;43(1):273-90.
•   Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V
  Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007 Feb;51(2):576-82. Epub 2006 Dec 4.
•   Smith MJ, Citron KM
  Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax. 1983 May;38(5):373-7.
•   Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F
  Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999 Sep;160(3):866-72.
•   Teeter JG, Bleecker ER
  Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest. 1998 Feb;113(2):272-7.
•   TIMPE A, RUNYON EH
  The relationship of atypical acid-fast bacteria to human disease; a preliminary report. J Lab Clin Med. 1954 Aug;44(2):202-9.
•   Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S
  Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother. 2003 Feb;15(1):66-70.
•   Varadi RG, Marras TK
  Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis. 2009 Oct;13(10):1210-8. Review.
•   Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N
  Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother. 2003 Oct;47(10):3117-22.
•   von Reyn CF, Waddell RD, Eaton T, Arbeit RD, Maslow JN, Barber TW, Brindle RJ, Gilks CF, Lumio J, Lähdevirta J, et al
  Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J Clin Microbiol. 1993 Dec;31(12):3227-30.
•   Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT
  Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1766-72.
•   Wallace RJ Jr, Brown BA, Griffith DE
  Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):215-21.
•   Wallace RJ, O'Brien R, Glassroth J, Raleigh J, Dutt A
  American Thoracic Society. Diagnosis and treatment of disease caused by non tuberculous mycobacteria. Am Rev Respir Dis 142:940-53, 1990
•   Yates MD, Pozniak A, Uttley AH, Clarke R, Grange JM
  Isolation of environmental mycobacteria from clinical specimens in south-east England: 1973-1993. Int J Tuberc Lung Dis. 1997 Feb;1(1):75-80.

Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi

Details for clinical trial NCT01298336